Anti-factor VIII inhibitory antibody (FVIII inhibitor) (FVIII inhibitor)

Anti-factor VIII inhibitory antibodies are polyclonal IgG immunoglobulins that neutralize the procoagulant activity of Factor VIII (FVIII), a vital cofactor in the blood clotting process (Lollar, 2004). These inhibitors typically develop as an immune response to exogenous FVIII replacement therapy in patients with congenital Hemophilia A or as an autoantibody in acquired hemophilia A (Kasper et al., 1975). By binding to specific domains (A2, A3, or C2) of the FVIII protein, these antibodies block its interaction with other clotting factors like Factor IXa and Factor X, effectively halting the intrinsic pathway of coagulation. The presence of these inhibitors is a major therapeutic challenge, as it renders standard FVIII concentrates ineffective and significantly increases the risk of morbidity and mortality from bleeding. Management strategies include the use of bypassing agents like recombinant Factor VIIa or activated prothrombin complex concentrates, which generate thrombin via alternative pathways. Modern treatments also utilize bispecific antibodies such as Emicizumab, which bridge Factor IXa and Factor X to restore coagulation function despite the presence of inhibitors (Oldenburg et al., 2017). Long-term eradication of the antibodies is often pursued through Immune Tolerance Induction (ITI), which involves regular, high-dose administration of FVIII to desensitize the immune system (Hay & DiMichele, 2012).

Other names

Factor VIII inhibitorsFVIII inhibitorsAnti-FVIII antibodiesFactor 8 inhibitorsAcquired Factor VIII inhibitors

Therapeutic strategies involve bypassing the Factor VIII-dependent step in the coagulation cascade using activated clotting factors, mimicking Factor VIII cofactor activity with bispecific antibodies like Emicizumab, or eradicating the inhibitory antibodies through Immune Tolerance Induction (ITI) and systemic immunosuppression (Hay & DiMichele, 2012; Oldenburg et al., 2017).